Company Overview of Advaxis, Inc.
Advaxis, Inc., a clinical development stage biotechnology company, focuses on developing immunotherapies for cancer and infectious diseases. The company’s Lm -LLO immunotherapy platform technology stimulates the immune system to induce antigen-specific anti-tumor immune responses involving innate and adaptive arms of the immune system by inhibiting the T-cells, Tregs, myeloid-derived suppressor cells, and MDSC to promote immunologic tolerance of cancer cells in the tumor. Its platform technology also facilitates the immune response by altering the tumor microenvironment to reduce immunologic tolerance in the tumors that makes the tumor more susceptible to immune attack. The company has appro...
305 College Road East
Princeton, NJ 08540
Founded in 2002
Key Executives for Advaxis, Inc.
Chief Executive Officer
Total Annual Compensation: $312.5K
Chief Scientific Officer and Executive Vice President
Total Annual Compensation: $371.7K
Compensation as of Fiscal Year 2013.
Advaxis, Inc. Key Developments
Advaxis, Inc. Announces Food and Drug Administration Acceptance of its Investigational New Drug Application to Commence Clinical Trials of ADXS-PSA in Combination with Merck's KEYTRUDA (Pembrolizumab) for Prostate Cancer
Dec 8 14
Advaxis, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to conduct a phase 1/2 clinical study to evaluate the combination of ADXS-PSA (ADXS31-142) with KEYTRUDA (pembrolizumab), marketed by Merck & Co., Inc., in patients with previously treated, metastatic castration-resistant prostate cancer (mCRPC). The clinical trial, which will be the first-in-human study of Advaxis's lead Lm-LLO immunotherapy product candidate in prostate cancer, is expected to begin patient enrollment in the first quarter of 2015. The open-label Phase 1/2 clinical trial is designed to evaluate the safety and efficacy of ADXS-PSA as a mono-therapy and in combination with KEYTRUDA, the first anti-PD-1 (programmed death receptor-1) therapy approved in the United States. KEYTRUDA is developed and marketed by Merck. The Phase 1 part of the study will be a dose-escalating study designed to establish the maximum tolerated dose of ADXS-PSA when used alone and in combination with KEYTRUDA. The Phase 2 portion will assess the safety and efficacy of the combination immunotherapy regimen. Advaxis and Merck will collaboratively oversee the conduct of the study and will use the results from the trial to determine the future clinical development program for the combination. ADXS-PSA and KEYTRUDA are members of a new class of cancer treatments known as immunotherapies, which are designed to enhance the body's own defenses in fighting cancer. Data from preclinical studies suggest that AdvaxisLm-LLO immunotherapies in combination with a PD-1 inhibitor may lead to an enhanced anti-tumor immune response.
Advaxis, Inc. Presents at LD Micro Conference, Dec-02-2014 04:00 PM
Nov 20 14
Advaxis, Inc. Presents at LD Micro Conference, Dec-02-2014 04:00 PM. Venue: Luxe Sunset Boulevard Hotel, 11461 Sunset Boulevard, Los Angeles, California, United States. Speakers: Daniel J. O’Connor, Chief Executive Officer, President and Director.
Advaxis Submits IND for Phase I/II Trial of ADXS-HPV and MEDI4736 in HPV-Associated Cancers
Nov 13 14
Advaxis has submitted an investigational new drug (IND) application to the US Food and Drug Administration (FDA) for its Lm-LLO immunotherapy ADXS-HPV (ADXS11-001) in combination with MEDI4736 to treat human papillomavirus (HPV) associated cancers. Following approval for the IND application, the company will conduct a Phase I/II trial of ADXS-HPV alone or in combination with MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, to treat advanced, recurrent or refractory HPV-associated cervical cancer and HPV-associated head and neck cancer. Scheduled to start in early 2015, the trial will evaluate the safety and efficacy of ADXS-HPV as monotherapy and in combination with MEDI4736. The Phase I part of the trial is expected to establish a recommended dose regimen of ADXS-HPV with MEDI4736, while the Phase II portion will evaluate the safety and efficacy of the combination.
Similar Private Companies By Industry
Recent Private Companies Transactions